Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes diagnostic and therapeutic molecular nuclear medicine, or MNM, products.

AAA is at the forefront of developing predictive, preventive and personalized tools and procedures that have the potential to radically transform healthcare. Our path to accomplishing this goal is by merging therapeuti... more >

Latest Newsmore >
11/17/17
Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017
$3.9 Billion All Cash Proposed Tender Offer by Novartis European Approval of Lutetium Lu 177 Dotatate* (Lutathera®) for GEP-NETs Recent Highlights: Sales for the third quarter of 2017 increased 39% compared to the third quarter of 2016 NETSPOT® unit sales per month increased 14% (from 915 to 1040) from June to September 2017 Entered into a Memorandum of Understanding with Novartis, pursuant to which Novartis proposes to make a $3.9 billion cash tender offer to acquire all the outs... 
10/30/17
Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis
Novartis Oncology Expertise to Facilitate Ongoing Development of Theragnostic Pipeline SAINT-GENIS-POUILLY, France, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), a leader in nuclear medicine theragnostics, today announced that it has entered into a Memorandum of Understanding with Novartis, pursuant to which Novartis proposes to make a cash tender offer to acquire all the outstanding shares of AAA, including shares represented by ... 
09/29/17
Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera®) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors
Completes First Theragnostic Radiopharmaceutical Pairing in Oncology SAINT-GENIS-POUILLY, France, Sept. 29, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide* (Lutathera®) for “the treatment of unresectable or metastatic, progressive, well differentiated (G... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources